(Q38124273)

29 August 2017

Antigen-based vaccination and prevention of type 1 diabetes (English)

1 reference

29 August 2017

0 references

Leonard C Harrison

1

1 reference

29 August 2017

John M Wentworth

2

1 reference

29 August 2017

Yuxia Zhang

3

1 reference

29 August 2017

Esther Bandala-Sanchez

4

1 reference

29 August 2017

Ralph M Böhmer

5

1 reference

29 August 2017

Alana M Neale

6

1 reference

29 August 2017

Natalie L Stone

7

1 reference

29 August 2017

Gaetano Naselli

8

1 reference

29 August 2017

Julian J Bosco

9

1 reference

29 August 2017

Priscilla Auyeung

10

1 reference

29 August 2017

Maryam Rashidi

11

1 reference

29 August 2017

Petra Augstein

12

1 reference

29 August 2017

Grant Morahan

13

1 reference

29 August 2017

1 October 2013

1 reference

29 August 2017

Current diabetes report

1 reference

29 August 2017

13

1 reference

29 August 2017

5

1 reference

29 August 2017

616-623

1 reference

https://scigraph.springernature.com/pub.10.1007/s11892-013-0415-7

29 August 2017

0 references

cites work

Vaccination against self to prevent autoimmune disease: the type 1 diabetes model

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Antigen-specific therapy for autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Regulatory T cells exert checks and balances on self tolerance and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Revisiting regulatory T cells in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Proinsulin-a pathogenic autoantigen in type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Insulin as an autoantigen in NOD/human diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Risk assessment, prediction and prevention of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Insulin resistance is a risk factor for progression to type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

The use of glipizide combined with intensive insulin treatment for the induction of remissions in new onset adult type I diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Effects of insulin in relatives of patients with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

GAD treatment and insulin secretion in recent-onset type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Preexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabetes in combination with anti-CD3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Transient blockade of CD40 ligand dissociates pathogenic from protective mucosal immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Latent autoimmune diabetes in adults (LADA) should be less latent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Normal incidence of diabetes in NOD mice tolerant to glutamic acid decarboxylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Therapy with GAD in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Decreased GAD(65)-specific Th1/Tc1 phenotype in children with Type 1 diabetes treated with GAD-alum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

The rising incidence of type 1 diabetes is accounted for by cases with lower-risk human leukocyte antigen genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Tests for genetic interactions in type 1 diabetes: linkage and stratification analyses of 4,422 affected sib-pairs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Proinsulin is encoded by an RNA splice variant in human blood myeloid cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Mucosal Antigen Primes Diabetogenic Cytotoxic T-Lymphocytes Regardless of Dose or Delivery Route

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0415-7

Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial

21 January 2018

1 reference

12 December 2020

Effects of oral administration of type II collagen on rheumatoid arthritis

1 reference

12 December 2020

Oral administration of human insulin to NOD mice generates CD4+ T cells that suppress adoptive transfer of diabetes

1 reference

12 December 2020

High-dose intravenous insulin infusion versus intensive insulin treatment in newly diagnosed IDDM.

1 reference

12 December 2020

Neonatal tolerization with glutamic acid decarboxylase but not with bovine serum albumin delays the onset of diabetes in NOD mice

1 reference

12 December 2020

Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity

1 reference

12 December 2020

Natural history of humoral immunity to glutamic acid decarboxylase in non-obese diabetic (NOD) mice

1 reference

12 December 2020

Transgenic expression of mouse proinsulin II prevents diabetes in nonobese diabetic mice

1 reference

12 December 2020

Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis

1 reference

12 December 2020

Suppression of the immune response by nasal immunization

1 reference

12 December 2020

Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide

1 reference

12 December 2020

Oral tolerance: mechanisms and therapeutic applications.

1 reference

12 December 2020

Antigen-specific mediated suppression of beta cell autoimmunity by plasmid DNA vaccination

1 reference

12 December 2020

Intensive therapy in adult insulin-dependent diabetes mellitus is associated with improved insulin sensitivity and reserve: a randomized, controlled, prospective study over 5 years in newly diagnosed patients

1 reference

12 December 2020

Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM.

1 reference

12 December 2020

Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.

1 reference

12 December 2020

10.1007/S11892-013-0415-7

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

0 references

1 reference